What does STOP-2 tell us about management of hypertension?

Comment

. 2000 Feb 19;355(9204):652; author reply 653.

doi: 10.1016/S0140-6736(05)72387-4.

Free article

Comment

A Siebenhofer et al. Lancet. 2000.

Free article

. 2000 Feb 19;355(9204):652; author reply 653.

doi: 10.1016/S0140-6736(05)72387-4.

No abstract available

Comment on

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Hansson L, et al. Lancet. 1998 Jun 13;351(9118):1755-62. doi: 10.1016/s0140-6736(98)04311-6. Lancet. 1998. PMID: 9635947 Clinical Trial.
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.
Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE. Hansson L, et al. Lancet. 1999 Feb 20;353(9153):611-6. doi: 10.1016/s0140-6736(98)05012-0. Lancet. 1999. PMID: 10030325 Clinical Trial.
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.
Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester PO, Hedner T, de Faire U. Hansson L, et al. Lancet. 1999 Nov 20;354(9192):1751-6. doi: 10.1016/s0140-6736(99)10327-1. Lancet. 1999. PMID: 10577635 Clinical Trial.